Stocks and Investing
Stocks and Investing
Fri, October 14, 2016
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Madhu Kumar Upgraded (ABUS) to Hold on, Oct 14th, 2016
Madhu Kumar of Chardan Capital, Upgraded "Arbutus Biopharma Corporation" (ABUS) to Hold on, Oct 14th, 2016.
Madhu has made no other calls on ABUS in the last 4 months.
There is 1 other peer that has a rating on ABUS. Out of the 1 peers that are also analyzing ABUS, all agrees with Madhu's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Friday, August 5th, 2016
Contributing Sources